目的 觀察注射用益氣復(fù)脈(凍干)對冠心病射血分?jǐn)?shù)保留的心力衰竭(HFpEF)患者的N末端B型腦鈉肽前體(NT-proBNP)、無創(chuàng)心功能相關(guān)指標(biāo)、明尼蘇達(dá)心力衰竭生活質(zhì)量評分(MLHFQ)的影響。方法 選擇128例2021年12月-2023年2月在中南大學(xué)湘雅二醫(yī)院心內(nèi)科住院的HFpEF患者為研究對象,隨機(jī)分為對照組及試驗組,最終納入對照組60例、試驗組61例。對照組予常規(guī)抗心衰治療,試驗組在常規(guī)治療的基礎(chǔ)上加用注射用益氣復(fù)脈(凍干),每次5.2 g,用250 mL 5 %葡萄糖注射液或0.9 %氯化鈉注射液稀釋后靜脈滴注,每日1次,兩組均連續(xù)治療7 d。觀察兩組治療前后NT-proBNP、無創(chuàng)心功能相關(guān)指標(biāo)、MLHFQ水平變化及安全性。結(jié)果 干預(yù)7 d后,試驗組NT-proBNP水平、無創(chuàng)心功能指標(biāo)中的射血前期(PEP)、MLHFQ評分均低于對照組,差異均具有統(tǒng)計學(xué)意義(P<0.05)。兩組不良反應(yīng)發(fā)生情況無顯著差異(P<0.05)。結(jié)論 注射用益氣復(fù)脈(凍干)可改善HFpEF患者的NT-proBNP、無創(chuàng)心功能指標(biāo)PEP和MLHFQ評分,且未見明顯臨床不良反應(yīng),可用于治療冠心病HFpEF患者。

Objective To observe the effect of Yiqi Fumai Lyophilized Injection on NT-proBNP, noninvasive cardiac function indices, and quality of life in patients with coronary heart disease HFpEF. Methods 128 patients with coronary heart disease HFpEF were selected as the study objects and randomly divided into experimental group and control group, 61 cases in experimental group and 60 cases in control group,finally. Patients in the control group were given conventional anti-heart failure treatment, and patients in the experimental group were given Yiqi Fumai Lyophilized Injection on the basis of the above treatment, 5.2 g each time, diluted with 250 ml 5 % Glucose Injection or 0.9 % Sodium Chloride Injection once a day, and both groups were used continuously for 7 seven days. N-terminal B-type brain natriuretic peptide precursor (NT-proBNP), noninvasive cardiac function related indicators, Minnesota Heart Failure Quality of Life Score (MLHFQ) level changes were observed in the two groups before and after treatment. Results After seven days of intervention, the level of NT-proBNP, non-invasive cardiac function index PEP and MLHFQ score in experimental group were lower than those in control group, with statistical significance (P < 0.05). Conclusion Yiqi Fumai Lyophilized Injection is effective in patients with CHD with ejection fraction retention heart failure, and no obvious clinical adverse reactions have been observed. It can be used as a new measure for the treatment of CHD HFpEF.

R974

國家自然科學(xué)基金資助項目(82172550)